Report
Martial Descoutures ...
  • Oussema Denguir

Poxel : De nouvelles opportunités s’offrent à Poxel

>Metavant sort du diabète - Poxel a annoncé vendredi matin que, Metavant, filiale de Roivant, son partenaire depuis 2 ans et demi dans le développement d’iméglimine aux USA et en Europe, a décidé de se retirer de la future phase 3. Cette décision, motivée par des considérations stratégiques propres à Roivant (« holding qui détient Metavant ») qui semble vouloir sortir du diabète, ne remet aucunement en cause, selon nous, le potentiel et l’avenir du projet. Bien a...
Underlying
Poxel SA

Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch